Nektar's Howard Robin plans sale of 418 shares
NEKTAR THERAPEUTICS (NKTR) is named as the issuer in a notice that Howard Robin intends to sell common stock under Rule 144.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NEKTAR THERAPEUTICS (NKTR) is named as the issuer in a notice that Howard Robin intends to sell common stock under Rule 144. The notice covers a planned sale of 418 shares of common stock held at Fidelity Brokerage Services LLC, with a stated market value of $30,086.93 as of August 18, 2026, on the NASDAQ market.
The shares to be sold arise from restricted stock vesting on August 14, 2026, identified as compensation from the issuer. The filing also lists prior sales of NKTR common stock by Howard Robin over the past three months, with the filer noting that the sale includes an amount to cover tax obligations from a vested equity award distribution.
Key Figures
Key Terms
Rule 144 regulatory
Restricted Stock Vesting financial
attorney-in-fact regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider sale of NKTR stock is indicated in this Form 144 notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.